Literature DB >> 2539946

Tumor necrosis factor alpha: a multifaceted peptide hormone.

M G Rosenblum1, N J Donato.   

Abstract

Homeostasis at the cellular level appears to be a complex state of equilibrium derived, in part, from multiple interactions among lymphokines, cytokines, growth factors, and hormones. Tumor necrosis factor (TNF-alpha) secreted by mitogen-stimulated macrophages and lymphotoxin (LT, TNF-beta) produced by mitogen-stimulated lymphocytes are two peptide hormones that share considerable homology in amino acid sequence and biological action. It has become increasingly evident that these factors, primarily involved in host defense, also mediate some responses to inflammatory, infectious, and neoplastic disease states. TNF-alpha is a low molecular weight (17,000-kdalton) peptide which seems to have a remarkably broad range of biological and immunologic effects, including antiviral action, growth regulation, and immunomodulation. These effects are shared by other lymphokines and cytokines such as interleukin 1 (IL-1), interferon alpha (IFN-alpha), interferon gamma (IFN-gamma), and TNF-beta. TNF-alpha also demonstrates both positive and negative cooperative growth-regulatory effects alone and in combination with antitumor drugs as well as with other bioactive peptides. Clinical trials are currently under way to determine the effectiveness of TNF-alpha as a single agent and in combination with biologic and chemotherapeutic agents against a variety of neoplastic diseases in man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539946

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  22 in total

1.  Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels.

Authors:  A Corti; G Fassina; F Marcucci; E Barbanti; G Cassani
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

2.  Induction of anti-mycobacterial and anti-listerial activity of human monocytes requires different activation signals.

Authors:  G Zerlauth; M M Eibl; J W Mannhalter
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

Review 3.  Role of mucosal T-cell-generated cytokines in epithelial cell injury.

Authors:  S R Targan; R L Deem; F Shanahan
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

4.  Administration of bacterial lipopolysaccharide elicits circulating tumor necrosis factor-alpha in neonatal calves.

Authors:  J L Adams; S D Semrad; C J Czuprynski
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

5.  Tetrandrine, a plant alkaloid, inhibits the production of tumour necrosis factor-alpha (cachectin) hy human monocytes.

Authors:  A Ferrante; W K Seow; B Rowan-Kelly; Y H Thong
Journal:  Clin Exp Immunol       Date:  1990-05       Impact factor: 4.330

6.  Regulation of murine macrophage function by IL-4: IL-4 and IFN-gamma differentially regulate macrophage tumoricidal activation.

Authors:  K Suk; S D Somers; K L Erickson
Journal:  Immunology       Date:  1993-12       Impact factor: 7.397

7.  Role of mesenchymal cell death in lung remodeling after injury.

Authors:  V A Polunovsky; B Chen; C Henke; D Snover; C Wendt; D H Ingbar; P B Bitterman
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Differentiation of human osteoblastic cells in culture: modulation of proteases by extracellular matrix and tumor necrosis factor-alpha.

Authors:  F S Panagakos; S Kumar
Journal:  Inflammation       Date:  1995-08       Impact factor: 4.092

9.  Modulation of proteases and their inhibitors in immortal human osteoblast-like cells by tumor necrosis factor-alpha in vitro.

Authors:  F S Panagakos; S Kumar
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

10.  Formation and mineralization of extracellular matrix secreted by an immortal human osteoblastic cell line: modulation by tumor necrosis factor-alpha.

Authors:  F S Panagakos; L P Hinojosa; S Kumar
Journal:  Inflammation       Date:  1994-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.